Owen N. Witte insider trades
Open-market stock purchases and sales by Owen N. Witte, Director at Allogene Therapeutics, Inc, from SEC Form 4 filings since Mar 14, 2017.
Track record: 0% of 1 scored buy are up 5% or more since purchase, averaging -88%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Jun 18, 2026 | ALLO Allogene Therapeutics, Inc | Bought (not open market) | — |